Bocheng Wu

Dual-acting Estrogen Receptor Modulator-Histone Lysine Demethylase Inhibitors

This paper develops dual-acting inhibitors combining estrogen receptor ligands with KDM inhibitors, showing potent anti-proliferative effects against both ER+ and ER- breast cancer cells in xenograft models.

Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of Deferiprone.

This study identifies KDM inhibition as a key anticancer mechanism of DFP and demonstrates PROTACs as a strategy to enhance its therapeutic potential.

Small molecule modulators of TOX protein re-invigorate T cell activity

This study identifies small molecule inhibitors of TOX protein that reverse T cell exhaustion and show cytotoxicity in T-ALL.

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy

This paper identifies a novel HDAC inhibitor, STR-V-53, that effectively targets HCC and enhances immunotherapy responses in mouse models.